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Abstract
Background: Transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases
affecting both humans and animals. They are associated with post-translational conversion of the
normal cellular prion protein (PrPC) into a heat- and protease-resistant abnormal isoform (PrPSc).
Detection of PrPSc in individuals is widely utilized for the diagnosis of prion diseases.
Methods: TSE brain tissue samples have been processed in order to quantitatively isolate PrPSc.
The protocol includes an initial homogenization, digestion with proteinase K and salt precipitation.
Results: Here we show that over 97 percent of the PrPSc present can be precipitated from
infected brain material using this simple salting-out procedure for proteins. No chemically harsh
conditions are used during the process in order to conserve the native quality of the isolated
protein.
Conclusion: The resulting PrPSc-enriched preparation should provide a suitable substrate for
analyzing the structure of the prion agent and for scavenging for other molecules with which it may
associate. In comparison with most methods that exist today, the one described in this study is
rapid, cost-effective and does not demand expensive laboratory equipment.
Background
Scrapie, bovine spongiform encephalopathy (BSE) and
Creutzfeldt-Jakob disease (CJD) are all related transmissi-
ble spongiform encephalopathies, the common major
causative agent of which is believed to be a protease- and
heat-resistant, beta-sheet rich isoform (PrPSc) of the nor-
mal cellular prion protein (PrPC) [1]. The patho-physio-
logical identity of the infectious agent has not been
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understood so far, although there is sufficient proof that
the conversion of PrPC to PrPSc plays a crucial role during
pathogenesis [2]. Clinically, the disease is characterized by
long incubation periods which, as in the recent crossover
of the bovine spongiform encephalopathy (BSE) agent to
humans, may be prolonged further when the disease is
transmitted from one species to another. Necropsy find-
ings from TSE cases generally show accumulation of PrPSc
in the brain, accompanied by extensive neurodegenera-
tion, which is also the major cause of fatality. Similar de-
posits have been demonstrated as well, in some of the
peripheral organs and the lymphoreticular compartment
in certain species [3,4]. Today, the ultimate confirmation
of the disease comes only after post-mortem examination
of the brain, even though extensive research being carried
out in the field offers hope for pre-clinical diagnosis
through the detection of PrPC in tonsils or body fluids.
Clinical signs of neurodegeneration, supported by the
presence of characteristic microscopic lesions and PrPSc in
the brain [5] are signs that eventually lead to the diagnosis
of TSEs. As well, the clinical indications, histopathological
symptoms and glycoform pattern of PrPSc isolated from
experimental animals are typical of the 'strain' or species
origin of the inoculums [6]. A number of in vitro assays
have been reported for the detection of PrPSc in the tissue,
including the dot-blot immunoassay, enzyme-linked im-
munosorbent assay (ELISA), immunocytochemistry,
Western blot analysis, and recently, capillary electro-
phoresis [7–12]. At present, the template source of PrPSc
for all these procedures is either the crude brain homoge-
nate or a harshly processed preparation called scrapie as-
sociated fibrils (SAF). While these procedures take
relatively less time to perform, in vivo bioassays requiring
the inoculation of laboratory animals such as mice or
hamsters with the infected material have been used over
the years for the detection of prion diseases. The main dis-
advantage of the bioassay technique however, lies in the
lengthy incubation period that incurs between inocula-
tion and appearance of clinical symptoms, compounded
by the expense of maintaining large animal colonies.
Therefore, scientists working in the field of prion diseases
most often prefer in vitro methods of diagnosis when there
is no absolute requirement to use laboratory animals.
In order to routinely detect PrPSc in specimens, reliable,
quantitative and yet relatively simple protocols are neces-
sary for its isolation. Here we report that over 97% of total
PrPSc in a brain sample may be detected in vitro following
an exceptionally short and simple precipitation method
of enrichment for the protein. The method was validated
within a European Union consortium of several laborato-
ries for standardization of the diagnosis of BSE and scrap-
ie by estimating the limiting dilution of detection of PrPSc
from infected brain. Using multiple preparations from
five different species, we also showed that the method de-
scribed herein concentrated PrPSc without altering the
PrPSc glycoform pattern, a quality that makes this proto-
col suitable for glycotype analyses for species or strain
identification of the infectious agent.
Methods
Experimental material
Infected brain tissues from mouse scrapie, strain ME7,
were obtained from FRCVD, Tubingen, Germany and
mouse BSE, strain 301 V from VLA, Weybridge, UK. Brain
tissues from sheep with natural scrapie or normal sheep
were obtained from the School of Veterinary Medicine,
Aristotle University, Thessaloniki (courtesy Prof. O. Papa-
dopoulos). BSE brain samples were obtained from VLA,
Weybridge, UK and the human CJD brain samples came
from recently reported cases of sporadic CJD (sCJD) from
within Greece [13]. All tissues were stored at -70C until
use. Autolytic deterioration was observed only in tissues
from the BSE cases due to handling during transportation
etc. Area of choice of the tissue for each species depended
on relevant data from our own and other laboratories.
Homogenization
A 10% homogenate of the tissue was prepared in cold ho-
mogenization buffer (0.5% IGEPAL CA-630 (NP-40) and
0.5% sodium deoxycholate in phosphate buffered saline,
pH 7.4) using a polytron homogenizer (Kinematica, Swit-
zerland) at setting 4, twice for 6 seconds each. For limiting
dilution experiments, the polytron was replaced with the
OmniGLH homogenizer (CAMLAB, UK) which worked
equally well with disposable probes, a very useful factor to
be considered while attempting multiple homogeniza-
tions with large number of samples. All homogenates
were stored in aliquots at -70C until use and thawed only
once.
Proteinase K treatment
On the day of use, 100 l of homogenate was diluted with
an equal volume of the homogenization buffer and incu-
bated with proteinase K (Sigma-Aldrich) for 1 hour at
37C with mild rocking. Concentrations of proteinase K
used varied with the species and are provided separately
with each figure. The reaction was stopped by the addition
of 5 mM PMSF (Sigma-Aldrich), a protease inhibitor.
Precipitation of PrPSc
The proteinase K digestion mixture was diluted with 300
l phosphate buffered saline (PBS) pH 7.4 and brought to
10% NaCl by the addition of an equal volume of 20%
NaCl in PBS containing 0.1% sarkosyl. The tube was kept
in ice for 10 minutes with occasional shaking. After cen-
trifugation at 16,000 g for 10 minutes at room tempera-
ture, the pellet was washed once with 25 mM Tris-HCl
buffer, pH 8.8 containing 0.05% sarkosyl (w/v) and cen-BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/23
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trifuged again at 16,000 g for 10 minutes. The final, en-
riched pellet was then resuspended in 2.5 loading buffer
10% v/v glycerol, 50 mM Tris pH 6.8, 2% w/v SDS, 3% -
mercaptoethanol and used for detecting PrPSc by western
blotting. Normally, for a starting volume of 100 l ho-
mogenate (10 mg brain equivalent) the final pellet was re-
suspended in the same volume (i.e. 100 l) of loading
buffer, of which 30 l (3 mg brain equivalent) was loaded
per lane for the western blot analysis.
In order to estimate any loss of PrPSc during the extraction
procedure, total proteins in the supernatants from both
the precipitation step and the wash step were precipitated
with 9 volumes of methanol overnight at -70C. After cen-
trifugation at 16,000 g, the supernatants were discarded
and the pellets resuspended in loading buffer (see above)
and used for western blot detection of PrPSc as described
below.
Polyacrylamide gel electrophoresis and western blotting of 
PrPSc
Proteins were subjected to electrophoresis using a 12 or
15% Laemmli sodium dodecyl sulfate polyacrylamide gel
(SDS-PAGE) and transferred to a PVDF membrane (Sig-
ma-Aldrich) and incubated with the primary antibody for
1 hr. This was followed by washes with PBS, pH 7.4 and a
further incubation for 35 minutes with the corresponding
secondary antibody. All incubations and washes were
done at room temperature. The primary antibodies were
SAL1 (manuscript in preparation), or 6H4 (Prionics AG,
Switzerland) depending on the species being tested. De-
tails of the use of primary and secondary antibodies is giv-
en in the figure legends. Following three washes of 15 min
each, the reaction was visualized using the CDP star (New
England Biolabs) chemiluminiscence detection technique
according to manufacturer's instructions. The membranes
were exposed to X-OMAT (Kodak) X-ray films for between
5 seconds to 5 minutes depending on the degree of posi-
tivity in the starting material.
The films were scanned (Hewlett Packard ScanJet 6300C)
and the positive signal analyzed and expressed as integrat-
ed optical density (IOD) using the Gel-Pro Analyzer 3.0
software. The percentage recovery of PrPSc in the final pel-
let (P) was then calculated using the formula:
Where P is the final pellet, W1 is the supernatant after salt-
precipitation and W2 is the supernatant after the final
wash.
Silver staining for total proteins
The initial crude homogenate, pellet after the final wash,
and the supernatants after salt precipitation and the final
wash, the latter two precipitated in 9 volumes of metha-
nol at -70C, were subjected to electrophoresis using an
SDS-PAGE system as described earlier. To avoid overload-
ing the gel, ten times less brain equivalent (0.3 mg) was
loaded for the crude homogenate than for the other sam-
ples (3 mg each). The procedure used for staining was a
standard method [27]. In short, the gel was fixed in 50%
methanol and 12% (v/v) acetic acid for 1 hour, followed
by incubation in 10% ethanol and 5% acetic acid (v/v) for
another hour. This was followed by treatment with 3.4
mM potassium dichromate in 2.8 mM nitric acid after
which the gel was washed with distilled water and incu-
bated for 30 min with shaking in 20% (w/v) silver nitrate.
The reaction was developed in 3% sodium carbonate con-
taining 0.5 ml formaldehyde 37% (paraformaldehyde)
per liter and stopped by the addition of 2.3 M citric acid
when the bands were clearly visible. Intensities of the
lanes due to total proteins were estimated as described
above.
Estimation of the degree of brain positivity for scrapie and 
BSE
Pooled homogenates of cerebellum from scrapie positive
sheep (P1) or brain stems from BSE positive cattle (P2)
were prepared as described above. Similarly, homoge-
nates were also prepared from healthy sheep (N1) or
healthy cattle (N2). In order to achieve different degrees
of tissue positivity, P1 and P2 were initially diluted up to
50% or 6.25% with N1 and N2, respectively, and the re-
sulting mixtures then used for precipitating PrPSc as de-
scribed in the steps above. Undiluted P1 and P2 served as
positive controls (100% positivity) whereas N1 and N2
served as negative controls for these experiments. Prior to
loading on the NuPage (Invitrogen) western blotting sys-
tem, the final pellet from each sample was subjected to
eleven 2-fold serial dilutions with loading buffer. The 6H4
monoclonal antibody was used to detect PrPSc on a PVDF
membrane and the positive signal was analyzed on a Bio-
Rad Fluor-S multiImager (Bio-Rad, USA).
Precipitation of PrPSc from different species
The validity of the current protocol to enrich for PrPSc
from different species and its use in glycotyping, the tech-
nique currently employed for species and strain identifica-
tion, was examined using both experimental and native
TSEs. Homogenates of mouse scrapie or mouse BSE whole
brain, native sheep scrapie cerebellum, BSE brain stem or
sporadic CJD cortex were used for this purpose. PrPSc was
precipitated from all species using 10% sodium chloride
as described above and detected on a western blot using
the polyclonal antibody SAL1. In order to perform glyco-
form analysis, band intensities of the double-, mono- or
Percentage recovery of PrP
IOD P 100
IOD W1 IOD W2 IOD
Sc = () ×
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non-glycosylated isoforms were determined in each sam-
ple and each glycoform was expressed as a percentage of
the total signal obtained.
Results
Percentage recovery of PrPSc in the final pellet
The migration pattern of PrPSc in the final enriched pellet
(P) and in the supernatants from the salt-precipitation
(W1) and wash (W2) steps from a sheep scrapie sample is
shown in Figure 1a. Loss of PrPSc in the discarded super-
natants in the two preceding steps was estimated to allow
the calculation of the degree of its recovery at the end of
the procedure. PrPSc-specific signal was discerned as the
classical three-band pattern representing the double-, mo-
no- and non-glycosylated isoforms, each of which was
typical of the individual species studied. The sum of the
signals obtained from P, W1 and W2 accounted for total
PrPSc in the starting material, and the percentage recovery
of PrPSc was calculated as described in Methods. As shown
in the inset table, as much as 97.4% of PrPSc was found in
the pellet with minimal loss in the supernatants, either
from the precipitation (2.08%) or the final wash step
(0.5%). These calculations are indicative from this partic-
ular experiment, whereas variability of the recoveries is
approximately 2%.
Estimation of total proteins using silver stain and estima-
tion of the degree of purification of PrPSc
Figure 1b shows staining for total proteins in the crude
homogenate (H) and in the fractions P, W1 and W2 that
were produced through the sodium salt precipitation pro-
cedure, each expressed as integrated optical densities
(IOD). Most cellular proteins remaining after protease K
digestion were present in supernatant W1 that was dis-
carded after salt precipitation, leaving relatively few pro-
teins in W2, the supernatant from the wash, and in the
final pellet, P. Intensity in lane H represents signal due to
total proteins in 0.3 mg brain equivalent of the initial
crude homogenate (the brain equivalent amount loaded
with the total homogenate was ten times less in order to
enable smooth running of the gel). All other lanes contain
3 mg brain equivalents each. The inset table shows values
for intensities in lanes H and P, and gives the degree of pu-
rification of PrPSc in lane P as a result of enrichment. As
may be seen, the IOD value in P (31.89) is 2 logs less than
in H (3121.5) indicating an 100-fold reduction in total
proteins in P. In conjunction with Figure 1a, where 97.4%
of the total PrPSc is shown to be present in P, it is clear that
the degree of purification of PrPSc in the final pellet was a
hundred times that of the initial homogenate, H.
Figure 1
Comparison of PrPSc and total protein during the
enrichment process. A) Western blots depicting the
migration pattern of PrPSc in the final enriched pellet (P) and
in the supernatants after the precipitation (W1) and the wash
(W2) steps in native sheep scrapie. Total proteins in W1 and
W2 were precipitated with 9 volumes of methanol over night
at -70C. SAL1 (1:3000) was used as the primary antibody
and alkaline phosphatase labeled goat anti-rabbit IgG (1:1500,
Roche) as the secondary antibody. Each lane contains 3 mg
brain equivalent. The table shows percentage recoveries of
PrPSc in P, W1 and W2. The estimations were made by first
determining the values for integrated optical density (IOD)
due to PrPSc for each lane. The sum of the values in P, W1
and W2 was then taken to be one hundred percent total
PrPSc in the starting material. Values due to PrPSc in each of
P, W1 and W2 were then deduced as percentages of the sum
total as described in Materials and Methods. Proteinase K
used was 30 g per ml homogenate. B) Silver staining of H
(starting undigested homogenate), P, W1 and W2 run on a
SDS-PAGE system. All lanes contain 3 mg brain equivalent
loads except for lane H which contains 0.3 mg of the same.
Molecular weight markers are shown in lane M. It may be
noticed that the some of the proteins present in H are also
present in W1, in the discarded supernatant after the precip-
itation step. Lanes P and W2 contain few detectable proteins.
The table provides a quantitative estimation of the degree of
purification of PrPSc in P after taking into account, signals due
to total proteins in lanes H and P respectively.
M      H      P       W1   W2
25 kDa -
Product Load per 
lane 
brain 
equivale
nt (mg)
Absorption IOD 
due to total 
proteins per mg 
brain equivalent
Degree of 
purification
Crude homogenate ‘H’ 0.3 3121.5 1
Pellet ‘P’ 3.0 31.89 100
PW 1 W 2
97.4% 2.08% 0.5%
P              W1           W2
25kDa-
A
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Estimation of degree of positivity in the tissue
Low limits of PrPSc detection are essential for a method to
be successfully applied to the determination of animals in
the pre-clinical stages of the TSE disease. It was therefore
considered mandatory to test the capability of the current
protocol for determining minimum positive tissue equiv-
alents in normal tissue homogenates spiked to various de-
grees with infected tissue. The lower limit of detection of
PrPSc using the current protocol was estimated using
pooled brain homogenates in order to avoid sample to
sample variations. Thus, pooled homogenates of cerebel-
lum from scrapie positive sheep (P1) or brain stems from
BSE positive cattle (P2) were used and similar homoge-
nates from healthy sheep (N1) or healthy cattle (N2)
served as negative controls. For both scrapie and BSE, the
positive (100% positivity) and negative (0% positivity)
homogenates were blended in ratios that provided final
mixtures containing 100%, 50%, or 6.5 % positive tissue
material. PrPSc was then precipitated from each of these
and the lowest limits of detection were determined using
western blot analysis. For both scrapie (Figure 2a) and
BSE (Figure 2b) samples, the lowest detection limit
ranged between 5–10 g brain equivalents.
Precipitation of PrPSc from different species
Since TSEs affect a variety of species, we also tested the ef-
ficiency of the sodium chloride method of PrPSc enrich-
ment on brain tissues of animals with natural and
experimental forms of TSEs. This was considered impor-
tant because of the species-related differences in the tissue
distribution and glycoform patterns of PrPSc. Brain equiv-
alents of 3 mg each in cases of scrapie, BSE and CJD, and
2 mg each in cases of mouse scrapie and mouse BSE were
loaded into each lane of an SDS-PAGE gel for western blot
Figure 2
Comparison of signal detection after blending PrPSc positive and negative homogenates in different ratios in
A) sheep scrapie and B) BSE. In each case, western blot analysis is shown for 100% positive tissue (top panels); 50% posi-
tive tissue (middle panels); and 6.25% positive tissue (bottom panels). Antibodies used were 6H4 (1:5000) and alkaline phos-
phatase labeled rabbit anti-mouse (1:5000), both from Prionics. Lanes show: C – 10% negative brain homogenate, unprocessed
and without proteinase K digestion; BM – molecular weight marker. Amounts listed above other lanes indicate the amount of
positive tissue equivalents loaded. Staining seen in the negative sample was considered to be due to improper digestion of the
tissue. Amount of proteinase K used was 100 g per ml homogenate in each case. The negative control and all test samples
were processed by the described salt precipitation protocol. The signal seen in lane C may be attributed to cellular prion pro-
tein, PrPC, present in normal brain tissue.
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analysis. It has been observed during routine laboratory
practice, however, that with animals suspected to have
TSEs or with doubtful positive signal for PrPSc, the load
per lane could be increased up to 10 mg brain equivalents,
thereby increasing the probability of detecting PrPSc. This
is accomplished by resuspending the final pellet in a
smaller volume of loading buffer. Mouse samples were
particularly useful as standard controls for glycoform
analyses as total brain homogenates were used in these
cases and thus uniform patterns, uninfluenced by the
choice of a certain area of the brain, were obtained on the
western blot. Banding patterns representative of each spe-
cies are shown in Figure 3. All samples were processed and
electrophoresed simultaneously. The sporadic CJD (sCJD)
case in lane 5 was of sporadic type 2 from Greece [13].
Quantitative estimations of the glycoforms for each spe-
cies are given in the histogram in Figure 4. Average values
and their standard errors were obtained for each species
after analyzing multiple samples in each case. In all cases,
the glycoform patterns presented by PrPSc matched those
previously reported in the literature [14–16] and was not
affected otherwise by the current method of enrichment.
Discussion
The first cases of BSE were reported in the United King-
dom [17] and since that time the cattle disease has been
implicated as a causative agent for new variant CJD in hu-
mans [18,19]. Fears have also been raised that BSE may
have crossed back into sheep [20,21] in the guise of sheep
scrapie. Given this scenario, two aspects of prion disease
monitoring need immediate attention. One is the pressing
need for the establishment of reliable, rapid and, at the
same time, sensitive protocols for the detection of TSEs
from both animal and human sources. The other is that
these methods should be easy to perform and cost-effec-
tive with minimal requirement for expensive equipment.
PrPSc remains the ultimate and sole determinant for a
confirmatory diagnosis of TSE. Given this fact, it seems
obvious that the successful, efficient extraction of this
molecule is of utmost importance. We have shown here
that it is now possible to enrich for PrPSc using sodium
chloride precipitation and obtain an end product contain-
ing up to 97.4% of the total PrPSc in the tissue. Loss of PrP-
Sc in the two wash steps during the procedure was
negligible and might well be attributed to the handling of
the material. The high degree of purification of PrPSc in
the pellet at the end of the method was indicated by a gen-
eral reduction in total proteins in the final enriched pellet
(Figure 1b) suggesting a 100-fold purification for PrPSc in
the latter. PrPSc could be extracted even more efficiently
from mouse species with a recovery of 99.7% (data not
shown), probably due to the uniform and homogeneous
constitution of the tissue involved. The method was also
Figure 3
Detection of PrPSc in TSEs from different host spe-
cies. Lanes show: 1 – mouse scrapie ME7, 2 – sheep scrapie,
3 – mouse BSE, 4 – BSE, 5 – sporadic CJD, 6 – normal sheep.
Lanes 1 and 3 contain 2 mg and lanes 2, 4, 6 contain 3 mg
brain equivalent load each. SAL 1 (1:3000) and alkaline phos-
phatase labeled goat anti-rabbit IgG (1:1500, Roche) were
the primary and the secondary antibodies respectively.
Amounts of proteinase K used per ml homogenate were 30
g in the cases of mouse scrapie, sheep scrapie and BSE and
50 g in the case of sCJD.
25kDa-
1      2     3     4      5     6 
Figure 4
Glycoforms of PrPSc isolated from different species.
Samples 1–5 represent ME7, sheep scrapie, mouse BSE, BSE
and sporadic CJD respectively. Percentages of specific glyco-
form are shown as average + standard error for each spe-
cies. Values shown were obtained from independent
experiments with 7 ME7 samples, 8 sheep samples, 2 mouse
BSE samples, 5 BSE samples and 5 sCJD samples. Bars repre-
sent percentage glycoforms of double, mono and non-glyco-
sylated bands according to the insert.
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tested in more than one species to establish that the elec-
trophoretic mobility of PrPSc thus obtained was not dis-
torted as reported recently with sodium phosphotungstate
salt [4]. Thus, PrPSc precipitated with sodium chloride salt
in this manner would be well suited for TSE strain and
species type analyses.
Early in the development of this protocol we noticed that
the low speed debris usually discarded during most PrPSc
purification procedures contained as much as 20–30% of
the total protein in the tissue (personal observation). It
was therefore considered useful to include tissue debris in
the extraction procedure described in this study and not to
use the common practice of 'clearing' tissue homogenates.
As would be expected, and as was indeed seen by silver
staining (Figure 1b), other molecules also were precipitat-
ed along with PrPSc. Although considered contaminants
in the present preparation, these molecules could become
suitable candidates when searching for other components
including proteins, non-proteins or nucleic acids [22] that
participate with PrPSc [23,24] in prion pathogenesis in the
different intermolecular interactions during the course of
the disease. The above protocol could be safely recom-
mended as an alternative confirmatory protocol of the
commercially available protocols taking into account the
achieved concentration was at least 20 times higher.
Though less popular than it was once, the SAF procedure
also precipitates PrPSc by aggregating it into fibrils,
through a rather harsh treatment with sarkosyl [25,26]
and high-speed centrifugation. Although it was the meth-
od of choice a few years ago, and still is considered as a
confirmatory diagnosis for TSEs by International Office of
Epizootics (IOE), SAF preparations are used less today be-
cause the method is tedious to perform and requires larger
quantities of starting tissue to offset heavy losses through-
out (with only 20% recovery of PrPSc). The low recovery is
indeed a problem, particularly with samples such as BSE
and CJD where there is a constant dearth of available ma-
terial. In our hands, at least fifty times the amount of tis-
sue reported in the present sodium chloride precipitation
procedure was required for the detection of PrPSc as SAFs
[10]. When the salt precipitated material was examined
for the presence of SAF's there weren't clearly detectable fi-
brilar structures thus making this protocol improper for
the detection of them.
The salt precipitation method described here gave satisfac-
tory results with all species of natural or experimental
forms of TSEs tested. The finding that the species origin of
the tissue did not affect the validity makes the procedure
universally applicable for enriching PrPSc in samples in-
tended both for diagnoses of prion diseases and for char-
acterization of the infectious agent. Additionally, the
observation that the glycoform pattern of PrPSc[14–16]
was not distorted after digestion with Proteinase K indi-
cates that the electrophoretic mobility of PrPSc was not af-
fected. This is an important issue to consider while
choosing any purification method for PrPSc because gly-
cotyping has become a useful tool for strain typing TSEs.
Conclusions
This study is the first where an attempt has been made to
estimate the recovery of PrPSc after its precipitation from
brain tissue. The major advantages of the procedure in-
clude speed, low cost, simplicity and reproducibility unaf-
fected by species origin. The ability to concentrate PrPSc
through precipitation should make it a putative protocol
of choice for detecting low amounts of PrPSc, as would be
present in preclinical cases. Several TSE testing laborato-
ries have applied succefully this protocol as a confirmato-
ry technique for PrPSc detection (Personal
communications). Future experiments to be undertaken
include estimations of infectious titers in the PrPSc en-
riched pellet and validation of the method in the detec-
tion of PrPSc from non-neural tissues.
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